v3.26.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Three Months Ended
March 31,
20262025
Total revenues$766,208 $745,145 
Less:
Cost of sales194,999 151,558 
R&D expenses
Research and early pipeline87,291 90,470 
Later-stage clinical programs36,177 14,291 
Marketed products55,328 53,970 
SG&A expenses
S&M expenses124,927 102,531 
G&A expenses133,363 103,585 
Other segment expense, net (1)
28,596 43,054 
Net income$105,527 $185,686 
(1)Other segment expense, net during the three months ended March 31, 2026 and 2025 include intangible asset amortization, interest income and expense, other income (expense) and income tax expense.
Schedule of Disaggregation of Total Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
March 31,
20262025
VOXZOGO$219,880 $213,754 
Enzyme Therapies:
VIMIZIM210,204 188,346 
NAGLAZYME130,074 114,290 
PALYNZIQ89,558 93,269 
BRINEURA47,104 40,362 
ALDURAZYME36,742 48,977 
KUVAN23,880 25,136 
ROCTAVIAN2,636 10,510 
Total net product revenues760,078 734,644 
Royalty and other revenues6,130 10,501 
Total revenues$766,208 $745,145 
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
March 31,
20262025
United States$242,944 $241,694 
Europe218,836 229,578 
Latin America108,164 88,282 
Rest of world153,392 126,113 
Total net product revenues marketed by the Company723,336 685,667 
ALDURAZYME net product revenues marketed by Sanofi36,742 48,977 
Total net product revenues$760,078 $734,644 
Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
March 31,
20262025
Customer A15 %14 %
Customer B11 12 
Customer C10 11 
Total36 %37 %